Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

655
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
655
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

719
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
719
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypernatremia and Polyuria in a Patient With Metastatic Breast Cancer.

JAMA oncology·2026
Same author

The Influence of Socioeconomic Status on Stage at Diagnosis and Survival in Young Breast Cancer Patients.

Clinical breast cancer·2025
Same author

Implementation of Quality Improvement Projects: A Practical Guide From the American Society of Breast Surgeons Patient Safety and Quality Committee.

Annals of surgical oncology·2025
Same author

Take charge during treatment: a protocol for a pilot study to evaluate the impact of exercise on cardiovascular biomarkers among black and white breast cancer patients undergoing treatment.

Cardio-oncology (London, England)·2025
Same author

Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.

Breast cancer research : BCR·2025
Same author

Race-related host and microbe transcriptomic signatures in triple-negative breast cancer.

NPJ breast cancer·2025
Same journal

Small Incisions, Big Impact-Robotic Surgery Is Revolutionizing Cancer Care.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Cancer.

Surgical oncology clinics of North America·2026
Same journal

TeleSurgery: The Present and the Future for Minimally Invasive and Robotic Surgery.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive and Robotic Surgery for Rectal Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive/Robotic Surgery for Colon Cancer.

Surgical oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery in Liver Transplantation.

Surgical oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Feb 18, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K

Triple-Negative Breast Cancer: Who Should Receive Neoadjuvant Chemotherapy?

Lubna N Chaudhary1, K Hope Wilkinson1, Amanda Kong1

  • 1Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.

Surgical Oncology Clinics of North America
|November 15, 2017
PubMed
Summary
This summary is machine-generated.

Neoadjuvant chemotherapy is crucial for treating aggressive triple-negative breast cancer, improving surgical outcomes and providing prognostic insights. Research focuses on enhancing treatment response and managing residual disease for better patient survival.

Keywords:
Breast-conserving surgeryNeoadjuvant chemotherapyTriple-negative breast cancer

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Related Experiment Videos

Last Updated: Feb 18, 2026

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

19.0K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.8K

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Triple-negative breast cancer (TNBC) presents significant treatment challenges due to its aggressive nature and high recurrence risk.
  • Systemic chemotherapy is a standard treatment for most TNBC patients, particularly those with locally advanced disease.
  • Neoadjuvant chemotherapy offers benefits such as tumor downstaging and increased rates of breast-conserving surgery.

Purpose of the Study:

  • To highlight the importance of neoadjuvant chemotherapy in triple-negative breast cancer treatment.
  • To emphasize the prognostic value of clinical and pathological responses in neoadjuvant therapy.
  • To outline current research directions focused on improving treatment efficacy and patient outcomes in the neoadjuvant setting.

Main Methods:

  • This section is not detailed in the provided abstract.
  • The abstract discusses clinical and pathological responses as key indicators.
  • Research trends in the neoadjuvant setting are mentioned.

Main Results:

  • Neoadjuvant chemotherapy aids in tumor downsizing for locally advanced triple-negative breast cancer.
  • Clinical and pathological responses during neoadjuvant therapy offer significant prognostic information.
  • The abstract implies positive outcomes associated with neoadjuvant approaches but does not present specific quantitative results.

Conclusions:

  • Neoadjuvant chemotherapy is an attractive and beneficial approach for all triple-negative breast cancer patients.
  • The prognostic information derived from treatment response is valuable for patient management.
  • Future research aims to improve pathologic complete response rates and outcomes for patients with residual disease.